The Effects of Mercaptopurine on Pulmonary Vascular Resistance and BMPR2 Expression in Pulmonary Arterial Hypertension
- 15 July 2020
- journal article
- letter
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (2), 296-299
- https://doi.org/10.1164/rccm.202003-0473le
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Systematic review with meta‐analysis: risk factors for thiopurine‐induced leukopenia in IBDAlimentary Pharmacology & Therapeutics, 2019
- Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signallingEuropean Respiratory Journal, 2019
- 3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient LungCirculation: Cardiovascular Imaging, 2018
- Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertensionNature Medicine, 2015
- Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohortsInflammatory Bowel Diseases, 2010
- Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertensionJCI Insight, 2005
- Initial apoptosis is followed by increased proliferation of apoptosis‐resistant endothelial cellsThe FASEB Journal, 2005
- Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.JCI Insight, 1998